Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
W@G2 01/07/13 for a 01/09/13 close
66.13 Kookiekook
W@G2 12/31/12 for a 01/04/13 close
66.23 Kookiekook
Thank you for the effort you have put forth in developing these rules. I look forward to the new contest.
I would like a little clarification on a few things:
1) Your example of the portfolio indicates purchases in 10% increments. So a division of 10,10,30,30,10and 10 is okay, but is a division of 15,15,15,15,15,25 also acceptable?? (i.e. what is the minimum % increment)
2) If wanting to sell part of a position, do you want it stated sell 50% of XXX or some otherway?
3) Are new buys to be indicated in $$amounts or how?
W@G2 12/26/12 for a 12/28/12 close
66.66 paulgmx1
65.68 Kookiekook
64.20 TFO
Good W@G Paul
W@G2 12/19/12 for a 12/21/12 close
67.11 Kookiekook
NEPT - Neptune Technologies and Bioresources - $1.71 (down from ~$2.50 since Monday)
Pending Catalyst - Completion of 2 Phase II Studies for CaPre during the 1st quarter of 2013. Planned Phase III sudy for CaPre by end of 2013
CaPre is a Krill Oil derivative intended for the control of Tirglycerides, HDL and LDL Choresterol (The medical condition referred to as Hyperlipidemia). Results released so far show no safety concerns and reduction of triglycerides of 25%.
Potential Market - approximately 63 million adults in US suffer from high triglycerides levels.
Competition
Lovaza (a GSK drug). Lovaza has annual sales exceeding $700 Million annaully. Yearly prescription cost average $2300
Generic Lovaza - None available at this time but may become availalbe during 2013
Over-the-Counter Fish Oil Supplements - Fish Oil supplements with 1g of Oemga 3 are becoming more available and can produce results similiar to Lovaza, The cost for a year supply is about $200.
My Conclusions:
Unless there is a substantially better result CaPre will be could wind up being approved but only find a limited market as a prescription drug unless it can marketed at a low price or it tested against existing treatments and shows a substantial improvement.
HEB - IMO is very difficult to predict. I personally believe the FDA is hoping that the ADCOM will find there is insufficent information on the safety of Apligen, allowing the FDA to to deny the NDA reinforcing their (the FDA's) prior decision that further testing is needed before approval can be granted. If on the otherhand the ADCOM does not find issue with the safety, approval of the NDA could happen very quickly and substanially earlier than the February 2nd decision date.
W@G1 12/17/12 for a 12/19/12 close
65.84 paulgmx1
65.31 Kookiekook
64.25 rayrohn
64.08 TFO
W@G1 12/17/12 for a 12/19/12 close
65.31 Kookiekook
Thanks to everyone for their kind words of congratulations. Particularly a special thank you to SSKILLZ1 for all his hard work in holding these contests.
CHTP - TaxiCaT while CHTP phase III study appeared to be sucessful. The FDA had already decided that the phase III was not adequate for approval of a NDA for Northera. Which means a new phase III study will probably be needed. Assuming CHTP is smart they will hold a meeting with the FDA to determine what further information is needed and with the FDA guidance design a new Phase study to aswer those concerns. This all takes time and money. Assuming 2-3 t set-up a meeting with the FDA, three months to initially design a new phase III study, another couple of months to get the FDA to review the new phase III study and make changes if needed. Then probably 18 months to run the phase III study, 2 months to collate the results. This adds up to time and money, probably 2+ years and probably dilution to finance the study. Until CHTP can announce its plans the stock price will lanquish around $1.00.
While I totally agree with jamarketing, before blindly dumping here I advise everyone to decide from a tax standpoint if selling now or after January 1st is best for them. Currently you could use the loss to offset gains for this gains for this year and even carrry-over $3000 in losses to offfset future gains in the market. BUT as we all know Congress writes the tax law and it changes constantly so I would not bet on the carry-over feature to present in the future.
If you have questions on your tax situation, please check with a tax professional. I am not a tax professional, and the statement above is solely my understanding of the current rules and not intended for particular advice to any individual or group.
Good W@G Ray
Good W@G Ray
Good W@G Paul
W@G2 12/12/12 for a 12/14/12 close
66.11 Kookiekook
W@G2 12/12/12 for a 12/14/12 close
W@G1 12/10/12 for a 12/12/12 close
64.54 Kookiekook
63.55 TFO
ZGNX
Deadjim, from the chart I would tend to agree, but Friday's ADCOM meeting and the negative vote (reported after hours) will drive the price down initially on Monday. It could be a good bounce play around 9:30 to 10 EST.
Thank you Paul
Thank you Ray
Good W@G Ray
W@G2 12/05/12 for a 12/07/12 close
65.49 Kookiekook
W@G2 12/05/12 for a 12/07/12 close
W@G1 12/03/12 for a 12/05/12 close
66.70 tfo
66.23 Kookiekook
65.50 rayrohn
Good W@G Paul
Thank you Paul
Thank you Ray
W@G2 11/28/12 for a 11/30/12 close
65.23 Kookiekook
W@G1 11/26/12 for a 11/28/12 close
65.61 Kookiekook
Good W@G Paul
CHTP - Sorry your numbers don't add up Trade2much.
Good W@G Paul
W@G2 11/21/12 for a 11/23/12 close
64.13 Kookiekook
62.50 rayrohn
Wasn't so much about negativity on TEXC as much as I was was tracking Molycorp (MCP) as expected a turnaround, and felt Friday with a slight gain indicated the beginning of that turnaround. Hopefully MPC will reach $10 shortly (a gain of 8.5% today is a decent start).
W@G1 11/19/12 for a 11/21/12 close
62.74 Kookiekook
61.36 TFO